Europe biosimilars market seen reaching $44.3B by 2033

By AI, Created 10:25 AM UTC, May 20, 2026, /AGP/ – Europe’s biosimilars market is projected to grow from $16.4 billion in 2026 to $44.3 billion by 2033, as patent expirations, regulatory support and lower-cost treatment options push wider adoption across oncology, immunology and rheumatology. The report highlights more than €50 billion in cumulative savings since 2006 and points to Germany, hospital pharmacies and autoimmune therapies as key growth drivers.

Why it matters: - Biosimilars are becoming a major tool for lowering biologic drug costs across Europe. - The shift is expanding patient access in oncology, immunology, rheumatology and other chronic disease areas. - The market’s growth is also reshaping how European health systems manage reimbursement, procurement and substitution.

What happened: - Persistence Market Research projects the Europe biosimilars market at US$16.4 billion in 2026. - The market is expected to reach US$44.3 billion by 2033. - The forecast implies a 15.3% CAGR from 2026 to 2033. - The report was released April 29, 2026. - The report says biosimilar adoption has already generated more than €50 billion in cumulative savings since 2006. - The report says savings reached €10 billion in 2023 alone. - Download the free sample for more details.

The details: - Patent expirations for blockbuster biologics are creating new entry points for biosimilars. - Lower-cost biosimilars are being used more often for autoimmune diseases, diabetes and inflammatory conditions. - The European Medicines Agency continues to provide a clear approval pathway with safety, efficacy and quality standards. - As of 2024, 106 biosimilars had been approved in Europe, and 89 remained commercially available. - Wider reimbursement and pricing approvals are supporting inclusion in public health programs. - Value-based healthcare and expanded hospital pharmacy distribution are adding to demand. - Continuous research and development investment is broadening the therapeutic pipeline. - Autoimmune diseases account for about 36% of the market. - Oncology is projected to grow at a 13.7% CAGR by 2033. - Hospital pharmacies are projected to grow at a 14.2% CAGR between 2026 and 2033. - Germany is projected to post a 15% CAGR and remain the largest national market. - The report cites Sandoz AG as one of the manufacturers expanding across therapeutic areas.

Between the lines: - The market is being pulled by both economics and policy, not just clinical demand. - Patent litigation and “evergreening” can still delay biosimilar launches and raise legal costs. - Conservative prescribing, lower brand-to-biosimilar price gaps and limited awareness are slowing uptake in some countries. - Switching patients from reference biologics to biosimilars could unlock more savings in chronic disease care. - Ten biologics are expected to lose IP protection over the next decade, creating an estimated €30 billion opportunity between 2030 and 2032. - Expansion beyond oncology into autoimmune disease, diabetes and inflammatory disorders could widen the market further.

What’s next: - More biosimilar launches are likely as additional biologics lose patent protection. - The report expects continued expansion in hospital-based distribution and physician-supported switching. - Sandoz launched Afqlir®, a biosimilar to Eylea® (aflibercept), in the UK in November 2025, with broader European expansion planned. - Several products, including Samsung Bioepis’s EKSUNBI, Formycon AG’s FYMSKINA and Reddy Holding GmbH’s ITUXREDI, have received EMA approval. - The competitive field includes Fresenius Kabi, Biogen, Celltrion, Pfizer, Amgen, Samsung Bioepis, Biocon, Viatris, Coherus BioSciences, Boehringer Ingelheim, Eli Lilly and Bio-Thera Solutions.

The bottom line: - Europe’s biosimilars market is moving from niche savings play to a core part of cost control and access strategy in healthcare.